中國抗體(03681.HK)內地總部建設正式開工
中國抗體(03681.HK)公布,全資附屬公司杏聯藥業於11月20日在蘇州工業園區上市企業產業園舉行新基地開工儀式,標誌著中國抗體內地總部建設正式開工。
中國抗體計劃未來兩年內投入10億元建設杏聯藥業新基地以作為公司內地總部,總建築面積超過7萬平米,包括生產車間、中試車間、研發中心、質檢中心、臨床研究中心及行政大樓等,建成產能約3.8萬升的生物反應車間;計劃2022年底整體土建竣工,基地建成後可年產單抗注射液 250至300萬瓶。(el/a) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.